335 related articles for article (PubMed ID: 12207869)
1. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
Konsil J; Dechasathian S; Mason DH; Stevens RE
J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
[TBL] [Abstract][Full Text] [Related]
2. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
Stevens RE; Limsakun T; Evans G; Mason DH
J Pharm Sci; 1998 Dec; 87(12):1531-4. PubMed ID: 10189261
[TBL] [Abstract][Full Text] [Related]
3. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
[TBL] [Abstract][Full Text] [Related]
4. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
5. Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.
Spina E; Tomson T; Svensson JO; Faigle JW; Bertilsson L
Ther Drug Monit; 1988; 10(4):382-5. PubMed ID: 3201523
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
[TBL] [Abstract][Full Text] [Related]
7. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
Garnett WR; Gilbert TD; O'Connor P
Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
Clausen SB; Read SC; Tulloch SJ
CNS Spectr; 2005 Dec; 10(12 Suppl 20):6-15. PubMed ID: 16344836
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
12. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
[TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
Reiz JL; Donnelly GA; Michalko K
Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
16. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
Datto C; Berggren L; Patel JB; Eriksson H
Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
[TBL] [Abstract][Full Text] [Related]
17. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
18. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
